WNK2 and low grade glioma: <h4>Introduction</h4>Mitogen-activated protein kinase pathway inhibitors (MAPKi) are an important therapeutic option for patients with unresectable, symptomatic or progressive pediatric low-grade gliomas (pLGGs).